An editorial suggests that the results of this meta-analysis add weight to a growing body of evidence suggesting that it is safe to defer administration of ADP-receptor antagonists while continuing aspirin and anticoagulation therapy to patients with non-ST elevation ACS being treated with an early invasive strategy until after the coronary anatomy has been defined. It concludes that for the approximate 20% of patients who are found to need surgical revascularisation, the avoidance of ADP-receptor antagonist exposure would facilitate a timelier and undoubtedly safer surgical procedure.